A canadian self-administered online survey to evaluate the impact of moderate-to-severe psoriasis among patients

Journal of Cutaneous Medicine and Surgery

Volumn 13, Issue 6, 2009, Pages 294-302

  Wasel, Norman ^a,b,c,d   Poulin, Yves ^a,b,c,d   Andrew, Robin ^a,b,c,d   Chan, Daphne ^a,b,c,d   Fraquelli, Elisa ^a,b,c,d   Papp, Kim ^a,b,c,d  

^a Stratica Medical Canada   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Janssen Ortho Inc   (Canada)

^d K Papp Clinical Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CROSS-SECTIONAL STUDY; FEMALE; HOSPITALIZATION; HUMAN; INTERNET; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; CANADA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERNET; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 77649219313     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2009.08066     Document Type: Review

References (53)

1. Nall L, Gulliver W, Charmley P. Search for the psoriasis susceptibility gene: the Newfoundland Study. Cutis 1999;64:323-9.
2. National Psoriasis Foundation. About psoriasis: psoriasis on specific skin sites. Available at: http://www.psoriasis.org/about/psoriasis/sites/ (accessed May 29, 2008).
3. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003;49(2 Suppl):S57-61.
4. Ashcroft DM, Li Wan Po A, Griffiths CE. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000;25:1-10.
5. Langley RG, Ho V, Lynde C, Papp KA. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches. J Cutan Med Surg 2006;9 Suppl 1:18-25.
6. Guenther L, Langley RG, Shear NH. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel 2004. J Cutan Med Surg 2004;8:321-37.
7. Krueger G, Koo J, Lebwohl M. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patientmembership survey. Arch Dermatol 2001;137:280-4.
8. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
9. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol 2007;57:1059-68.
10. Bhosle MJ, Kulkarni A, Feldman SR. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006;4:35.
11. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685-704.
12. Ciocon DH, Horn EJ, Kimball AB. Quality of life and treatment satisfaction among patients with psoriasis and psoriatic arthritis and patients with psoriasis only: results of the 2005 Spring US National Psoriasis Foundation Survey. Am J Clin Dermatol 2008;9:111-7.
13. Pearce DJ, Singh S, Balkrishnan R. The negative impact of psoriasis on the workplace. J Dermatolog Treat 2006;17:24-8.
14. Pariser DM, Bagel J, Gelfand JM. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 2007;143:239-42.
15. De Korte J, Mombers FM, Sprangers MA. The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol 2002;138:1221-7.
16. Augustin M, Kruger K, Radtke MA. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter crosssectional study in Germany. Dermatology 2008;216:366-72.
17. Dubertret L, Mrowietz U, Ranki A. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36.
18. Gelfand JM, Weinstein R, Porter SB. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:1537-41.
19. Perrott SB, Murray AH, Lowe J. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. Physiol Behav 2000;70:567-71.
20. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997;36:259-62.
21. Husted JA, Gladman DD, Farewell VT. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511-7.
22. Stern RS, Nijsten T, Feldman SR. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9:136-9.
23. Ware JE, Dewey JE, Gandek B. A manual for users of the SF-8 Health Survey. Lincoln (RI): QualityMetric Inc; 2001.
24. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
25. Fleischer AB, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 1999;26:210-5.
26. Garcia-Diez A, Foraster CF, Sebastian FV. What characterizes the severity of psoriasis? Results from an epidemiological study of over 3,300 patients in the Iberian region. Dermatology 2008;216:137-51.
27. Kimball AB, Jacobson C, Weiss S. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005;6:383-92.
28. Gupta MA, Gupta AK, Kirkby S. Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988;124:1052-7.
29. Griffiths CE, Iaccarino L, Naldi L. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin Exp Rheumatol 2006;24(1 Suppl 40):S72-8.
30. Jiaravuthisan MM, Sasseville D, Vender RB. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007;57:1-27.
31. Naldi L, Chatenoud L, Linder D. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7.
32. Kimball AB, Gladman D, Gelfand JM. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008;58:1031-42.
33. Neimann AL, Shin DB, Wang X. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55: 829-35.
34. Mallbris L, Akre O, Granath F. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30.
35. Gelfand JM, Neimann AL, Shin DB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
36. Gladman DD, Antoni C, Mease P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2:14-7.
37. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003;4:441-7.
38. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602-7.
39. Rapp SR, Feldman SR, Exum ML. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
40. Ware JE Jr, Kosinski M, Bjorner JB, et al. User's manual for the SF-36 v2TM Health Survey (Second Edition). Lincoln (RI): QualityMetric, Inc.; 2007.
41. Yang M, Wallenstein G, Hagan M. Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt) 2008;17:113-21.
42. Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512-8.
43. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96.
44. Statistics Canada. Portrait of the Canadian population in 2006, by age and sex: national portrait. Available at: http://www12. statcan.ca/english/ census06/analysis/agesex/NatlPortrait3.cfm (accessed July 21, 2008).
45. The Internet experience of younger and older Canadians. Innovation Analysis Bulletin. Ottawa (ON): Statistics Canada; 2006.
46. Statistics Canada. Income of Canadians. Available at: http://www.statcan.ca/Daily/English/080505/d080505a.htm (accessed July 21, 2008).
47. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18.
48. Pettey AA, Balkrishnan R, Rapp SR. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol 2003;49:271-5.
49. Rhodes SD, Bowie DA, Hergenrather KC. Collecting behavioural data using the world wide web: considerations for researchers. J Epidemiol Community Health 2003;57:68-73.
50. Rankin KM, Rauscher GH, McCarthy B. Comparing the reliability of responses to telephone-administered versus self-administered Web-based surveys in a case-control study of adult malignant brain cancer. Cancer Epidemiol Biomarkers Prev 2008;17: 2639-46.
51. Thomas CL, Finlay AY. The 'handprint' approximates to 1% of the total body surface area whereas the 'palm minus the fingers' does not. Br J Dermatol 2007;157:1080-1.
52. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
53. Hahn HB, Melfi CA, Chuang TY. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol 2001;45:44-8.